Call Options

20 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$23.66 - $32.73 $1.45 Million - $2 Million
-61,100 Reduced 88.17%
8,200 $201,000
Q2 2024

Aug 15, 2024

BUY
$24.46 - $40.4 $237,262 - $391,880
9,700 Added 16.28%
69,300 $1.84 Million
Q1 2024

May 07, 2024

BUY
$36.38 - $52.31 $1.05 Million - $1.51 Million
28,800 Added 93.51%
59,600 $2.46 Million
Q4 2023

Feb 14, 2024

BUY
$14.19 - $42.33 $79,464 - $237,048
5,600 Added 22.22%
30,800 $1.27 Million
Q3 2023

Nov 14, 2023

BUY
$19.64 - $28.21 $151,228 - $217,217
7,700 Added 44.0%
25,200 $494,000
Q2 2023

Aug 11, 2023

SELL
$21.73 - $31.43 $17,384 - $25,144
-800 Reduced 4.37%
17,500 $434,000
Q1 2023

May 16, 2023

SELL
$26.15 - $37.26 $1.02 Million - $1.45 Million
-38,900 Reduced 68.01%
18,300 $499,000
Q4 2022

Feb 14, 2023

BUY
$32.47 - $57.24 $1.25 Million - $2.21 Million
38,600 Added 207.53%
57,200 $1.96 Million
Q3 2022

Nov 14, 2022

SELL
$41.87 - $57.99 $213,537 - $295,749
-5,100 Reduced 21.52%
18,600 $828,000
Q2 2022

Aug 15, 2022

SELL
$36.01 - $74.24 $1.67 Million - $3.45 Million
-46,500 Reduced 66.24%
23,700 $998,000
Q1 2022

May 16, 2022

SELL
$60.27 - $81.57 $307,377 - $416,006
-5,100 Reduced 6.77%
70,200 $4.72 Million
Q4 2021

Feb 14, 2022

BUY
$65.85 - $96.21 $217,304 - $317,493
3,300 Added 4.58%
75,300 $6.19 Million
Q3 2021

Nov 15, 2021

SELL
$73.2 - $107.87 $270,840 - $399,119
-3,700 Reduced 4.89%
72,000 $5.92 Million
Q2 2021

Aug 11, 2021

SELL
$60.45 - $84.26 $368,745 - $513,986
-6,100 Reduced 7.46%
75,700 $5.83 Million
Q1 2021

May 17, 2021

SELL
$58.19 - $91.37 $4.24 Million - $6.65 Million
-72,800 Reduced 47.09%
81,800 $5.41 Million
Q4 2020

Feb 16, 2021

BUY
$20.19 - $84.93 $2.85 Million - $12 Million
141,200 Added 1053.73%
154,600 $13.1 Million
Q3 2020

Nov 16, 2020

SELL
$22.99 - $36.34 $643,720 - $1.02 Million
-28,000 Reduced 67.63%
13,400 $316,000
Q2 2020

Aug 14, 2020

BUY
$29.88 - $56.74 $313,740 - $595,770
10,500 Added 33.98%
41,400 $1.39 Million
Q1 2020

May 15, 2020

SELL
$33.0 - $54.5 $118,800 - $196,200
-3,600 Reduced 10.43%
30,900 $1.25 Million
Q4 2019

Feb 14, 2020

BUY
$15.39 - $44.38 $530,955 - $1.53 Million
34,500 New
34,500 $1.42 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $997M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.